See every side of every news story

Published 27 days ago • loading... • Updated 27 days ago

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

Summary by The Billings Gazette

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…

29 Articles

29 Articles

Montana Standard

+27 Reposted by 27 other sources

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…

27 days ago

Read Full Article

FDA Green Lights Novel Oral GLP-1 Drug with 10X Better Exposure Than Competitors

New oral GLP-1 shows 10X higher exposure vs competitors in trials. Phase 1 studies start 2H 2025 for obesity treatment. Get the clinical timeline.

27 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources29

Leaning Left1Leaning Right1Center14Last Updated26 days agoBias Distribution

88% Center

Bias Distribution

88% of the sources are Center

88% Center

+9

Untracked bias

+4

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Billings Gazette broke the news in Billings, United States 27 days ago on Tuesday, August 5, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics